Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof

A method for improving lipid metabolism and/or sugar metabolism in a subject, comprising administering an effective amount of a lactic acid producing bacterium, a treated product thereof, or a mixture thereof to a subject in need thereof,

• wherein the lactic acid producing bacterium has dual-agonistic activities on a peroxisome proliferator activated receptor (PPAR)α and a peroxisome proliferator activated receptor (PPAR)γ, wherein
• (a) the PPARα agonistic activity is about 70% or more of the PPARα agonistic activity of a positive control, as measured by a PPARα reporter assay;
• and
• (b) the PPARγ agonistic activity is about 30% or more of the PPARγ agonistic activity of a positive control, as measured by a PPARγ reporter assay.

A method for preventing, improving, or treating a lipid metabolism disorder and/or sugar metabolism disorder in a subject, comprising administering an effective amount of a lactic acid producing bacterium, a treated product thereof, or a mixture thereof to a subject in need thereof,

• wherein the lactic acid producing bacterium has dual-agonistic activities on a peroxisome proliferator activated receptor (PPAR)α and a peroxisome proliferator activated receptor (PPAR)γ, wherein
• (a) the PPARα agonistic activity is about 70% or more of the PPARα agonistic activity of a positive control, as measured by a PPARα reporter assay;
• and
• (b) the PPARγ agonistic activity is about 30% or more of the PPARγ agonistic activity of a positive control, as measured by a PPARγ reporter assay.

A method for reducing subcutaneous fat and/or visceral fat or preventing accumulation of subcutaneous fat and/or visceral fat, comprising administering an effective amount of a lactic acid producing bacterium, a treated product thereof,or a mixture thereof to a subject in need thereof,

• wherein the lactic acid producing bacterium has dual-agonistic activities on a peroxisome proliferator activated receptor (PPAR)α and a peroxisome proliferator activated receptor (PPAR)γ, wherein
• (a) the PPARα agonistic activity is about 70% or more of the PPARα agonistic activity of a positive control, as measured by a PPARα reporter assay;
• and
• (b) the PPARγ agonistic activity is about 30% or more of the PPARγ agonistic activity of a positive control, as measured by a PPARγ reporter assay.